$99.06
0.71[0.72%]
At close: Apr 25
$99.06
0[0.00%]
After Hours: 4:33PM EDT
Latest News for Novartis Stock (NYSE:NVS)
Novartis Stock (NYSE: NVS)
Categories: All
Thursday, April 25, 2024
Wednesday, April 24, 2024
- BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116Benzinga Newsdesk - 1 day ago
- Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And SafetyBenzinga Newsdesk - 1 day ago
Tuesday, April 23, 2024
- FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine TumorsVandana Singh - 2 days ago
- Novartis Radioligand Therapy Lutathera FDA Approved First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine TumorsBenzinga Newsdesk - 2 days ago
- Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?Piero Cingari - 2 days ago
- Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual OutlookVandana Singh - 2 days ago
- Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'Shanthi Rexaline - 2 days ago
- Novartis shares are trading higher after the company reported better-than-expected Q1 financial results.Benzinga Newsdesk - 2 days ago
- Novartis Now Expects 2024 Net Sales To Grow High Single To Low Double-Digit (Prior Mid-Single-Digit) And Core Operating Income To Grow Low Double-Digit To Mid-Teens (Prior High Single-Digit)Benzinga Newsdesk - 2 days ago
- Novartis Q1 2024 Adj EPS $1.80 Beats $1.67 Estimate, Sales $11.829B Beat $11.433B EstimateBenzinga Newsdesk - 2 days ago
Sunday, April 21, 2024
Friday, April 19, 2024
Wednesday, April 17, 2024
- Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 YearsVandana Singh - Apr 17, 2024, 11:48AM
- Novartis Announced Earlier, Continuous Kesimpta Treatment For Up To Six Years Showed Sustained Efficacy In Recently Diagnosed (≤3 Years) Treatment-naïve People Living With Relapsing Multiple Sclerosis In Analysis Of Alithios Open-label Extension StudyCharles Gross - Apr 17, 2024, 5:28AM
Tuesday, April 16, 2024
Monday, April 15, 2024
- MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per ShareBenzinga Newsdesk - Apr 15, 2024, 3:55PM
- Novartis Fabhalta Data Show Clinically Meaningful And Statistically Significant Proteinuria Reduction Of 38.3% Versus Placebo For Patients With IgA NephropathyBenzinga Newsdesk - Apr 15, 2024, 2:01PM
Thursday, April 11, 2024
- Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential ImpactVandana Singh - Apr 11, 2024, 2:47PM
- Looking At Novartis's Recent Unusual Options ActivityBenzinga Insights - Apr 11, 2024, 10:16AM
- Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In MilestonesBenzinga Newsdesk - Apr 11, 2024, 7:22AM
- Novartis Tender Offer For Morphosys Commences @€68.00/ShareCharles Gross - Apr 11, 2024, 4:52AM
Wednesday, April 10, 2024
Tuesday, April 09, 2024
- Novartis Says 'In light of recently evolving regulatory guidance on intake limits for nitrosamines in medications, enrollment of new patients in ribociclib early breast cancer (eBC) studies has been paused in alignment with health authorities.'Benzinga Newsdesk - Apr 9, 2024, 4:37PM
- Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst SaysVandana Singh - Apr 9, 2024, 2:26PM
- Novartis To Axe 680 Development Jobs Amid Global Reshuffle: ReportNabaparna Bhattacharya - Apr 9, 2024, 12:33PM
Monday, April 08, 2024
Thursday, April 04, 2024
- Why Is Novartis Stock Trading Higher On Thursday?Vandana Singh - Apr 4, 2024, 2:09PM
- Novartis shares are trading higher after the company confirmed plans to file for Pluvicto pre-taxane label expansion in the second half 2024 based on data from its Phase III PSMAfore study.Benzinga Newsdesk - Apr 4, 2024, 12:18PM
- Novartis Earlier Said It Plans To File For Pluvicto Pre-Taxane Label Expansion In H2 2024 Based On Data From Phase III PSMAfore StudyBenzinga Newsdesk - Apr 4, 2024, 12:12PM
Monday, April 01, 2024
Wednesday, March 27, 2024
Monday, March 25, 2024
- Novartis Pharmaceuticals Canada Announced Health Canada Grants Approval Of The Eye-tracking Neurological Assessment For Multiple Sclerosis For Use In Tracking Disease Progression In People Living With MSCharles Gross - Mar 25, 2024, 5:15PM
- Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth FundNeil Dennis - Mar 25, 2024, 10:27AM
Friday, March 22, 2024
- Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly SurgeVandana Singh - Mar 22, 2024, 10:34AM
- On 21 March 2024, The CHMP Adopted A Positive Opinion, Recommending The Granting Of A Marketing Authorization For Novartis' Fabhalta1, Intended For The Treatment Of Paroxysmal Nocturnal HaemoglobinuriaCharles Gross - Mar 22, 2024, 7:15AM
Wednesday, March 20, 2024
Tuesday, March 19, 2024
Friday, March 15, 2024
Monday, March 11, 2024
Friday, March 08, 2024
Thursday, March 07, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
- Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium EpidemicNatan Ponieman - Mar 5, 2024, 4:45PM
- FDA Approves JUBBONTI By SANDOZ INCBenzinga Newsdesk - Mar 5, 2024, 10:26AM
- Novartis AG Says Shareholders Approve Dividend Increase To CHF 3.30 (+3.1%) Per Share For 2023; Representing A 3.7% Yield And ~58% Payout Of Free Cash FlowBenzinga Newsdesk - Mar 5, 2024, 9:23AM